



Biopharmaceutical company  
since 1937

# SAMSON-MED

---

COMPANY CATALOG

---

# TABLE OF CONTENTS

## BIOPHARMACEUTICAL COMPANY SAMSON-MED

About the Company  
3

History  
8

Product list  
10

Geography  
19

R&D center  
20

Pipeline  
21

Production launch  
22

# OUR THERAPEUTIC AREAS



DERMATOVENEROLOGY



INFECTIOUS  
DISEASES



CARDIOLOGY



GENERAL THERAPY



ONCOLOGY



ORTHOPEDICS



PULMONOLOGY



UROLOGY



SURGERY

RUSSIAN PRODUCER

OF NON-RNDA BIOLOGICAL  
MEDICINES

EXTRACTED  
FROM ANIMAL RAW  
MATERIALS

#### Our mission

WE USE OUR UNIQUE  
COMPETENCIES AND EXPERTISE IN THE  
FIELD OF BIOPHARMACEUTICAL PRODUCTS  
RESEARCH AND PRODUCTION TO IMPROVE  
HUMAN QUALITY OF LIFE AND HEALTH



# MED



## OUR VIEWS

Samson-Med is one of the first pharmaceutical companies in the Russian Federation. The company carries out a full range of activities from development and research to the full-cycle biological products production and their marketing support in the markets of Russia and the near abroad. Thanks to over 80 years of unique experience, Samson-Med has maintained a strong position in the pharmaceutical segment of biological drugs and is a center of scientific and technological expertise.

#### Our values

- Years of experience and competence building
- High quality of products
- Affordable biopharmaceutical products
- Long term partnerships

## OUR PRODUCTION SITE IS AT ST. PETERSBURG, MOSKOVSKOE SH.

The company carries out a full range of activities from development and research to the full-cycle biological products production and their marketing support in the markets of Russia and the near abroad

# 82 years


in the pharmaceutical  
market




## OUR NUMBERS

- > 30 million vials per year
- > 360 highly qualified employees
- 6 export countries
- 1.2 billion rubles - revenue in 2018
- > 5 billion rubles investment in production
- > 10 products in portfolio
- > 10 products in development

## OUR REVENUE, BILLION RUB



# OUR HISTORY



## 1937. Foundation of the Company

In 1937, the facility for the processing of raw materials was created at the Kirov meat processing plant in order to obtain enzymes. At the time of its foundation, the plant produced the simplest preparations from endocrine-enzyme raw materials: pepsin, hematogen, gastric acid

## 1941–1945. World War II

Samson-Med Company launches the production of penicillin and insulin, which are important for the military industry. The company was the first to introduce insulin production using ion-exchange resins. During the war, the territory of the plant had strategic importance: there was a line of defense, and the highest point of the plant was the observation and coordination center

## 1963. Production of Chymopsin and Chymotrypsin

The company began production of Chymopsin and Chymotrypsin, which are still used in surgery and dentistry.

## 1970s. Start of production of blood substitutes

A number of plasma-substituting drugs were developed and launched into production together with the Leningrad Hematology and Transfusiology Research Institute: Disol, Trisol, Acesol

## 1975-1980. Start of production of Cytochrome C and infusion preparations

## 1980s. Beginning of the production of peptide biological products

## 1998. Launch of Samprost®

## 2010. New Manufacturing Plant and Pharmaceutical Cluster

## 2016. A project of strategic importance

## 2017. The 80th Anniversary

## 2019. The second phase of the new plant construction

The development of an injection form of Cytochrome C was completed together with the Leningrad Hematology and Transfusiology Research Institute. The production of infusion solutions was launched on the basis of the blood substitutes workshop. The workshop of blood substitutes and infusion solutions was considered an object of special purpose, since it produced drugs not only for the civilian population, but also “special orders” for the army: Aminopeptide, Hydrolysin, etc.

Together with the S.M. Kirov Military-Medicine Academy has developed a number of peptide drugs, among which Thymalin® and Samprost®. At that time, Samson-Med product portfolio included more than 40 types of drugs

Samson-Med company has registered and started production of the Samprost® drug, which became one of the first biological products for the treatment of chronic prostatitis in the Russian Federation

Samson-Med becomes a member of Saint-Petersburg Pharmaceutical cluster. The Resolution of the Government of St. Petersburg on the construction of a new production complex Samson-Med in the Pushkinskaya Industrial Zone had been signed

Samson-Med becomes a resident of Saint-Petersburg Localization and Import Substitution Center. The project of the new Samson-Med manufacturing plant construction is recognized as strategic one for the city by the Saint-Petersburg Government Resolution

The company celebrates its 80th anniversary. The project of building a new plant is being actively implemented, the R&D direction is developing: many projects are launched to modernize existing products and technologies, and active cooperation is being conducted with leading research institutes of the Russian Federation to develop new products

The company completes the second phase of the new plant construction and completes the rebranding project

# PRODUCT LIST

## Rx DRUGS

### THYMALIN®

**Generic name:**  
thymus extract

#### ONCOLOGY

**COMMERCIAL FORM:**

- lyophilisate for the preparation of a solution for intramuscular administration, 10 mg - vial No. 5 and No. 10



**Indications:**

- infectious purulent and septic processes;
- persistent impairment of the thymus function (radiation sickness, thymus tumors, surgical removal of the thymus);
- acute and chronic viral and bacterial infections;
- impairment of regenerative processes;
- immunodepression and inhibition of the blood formation after the chemotherapy or the X-ray therapy in cancer patients

### CYTOCHROME C

**Generic name:**  
cytochrome C

#### CARDIOLOGY

**COMMERCIAL FORM:**

- lyophilisate for the preparation of a solution for intravenous and intramuscular administration, 10 mg – vial No. 5



**Indications:**

- asphyxia of the newborn;
- severe injuries;
- before and after surgery (to prevent shock), during the period of remission of bronchial asthma with the presence of respiratory failure, in patients with chronic obstructive pulmonary disease and heart failure;
- viral hepatitis complicated by hepatic coma;
- poisoning with sleeping pills and carbon monoxide

### LYDASE

**INN:**  
hyaluronidase

#### DERMATOVENEROLOGY

**COMMERCIAL FORM:**

- lyophilisate for a solution for injection and topical application, 64 CU (conventional units) - vial No. 5 and No. 10



**Indications:**

- burn, traumatic, postoperative scars;
- long-term non-healing ulcers (including radiation);
- Dupuytren's contracture;
- joint stiffness, joint contractures (after inflammatory processes, injuries), osteoarthritis, ankylosing spondylitis, severe diseases of the lumbar discs;
- chronic peritendinitis, scleroderma (skin manifestations), hematoma of soft tissues of superficial localization;
- preparation for skin plastic surgery for scarring;
- pulmonary tuberculosis (complicated by nonspecific lesions of the bronchi), inflammatory processes in the upper respiratory tract and bronchi with obstruction;
- traumatic lesions of the nerve plexuses and peripheral nerves (plexitis, neuritis);
- hyphema, hemophthalmia, retinopathy of various etiologies

### SAMPROST®

**Generic name:**  
prostate extract

#### UROLOGY

**COMMERCIAL FORM:**

- lyophilisate for the preparation of a solution for intramuscular administration, 5 mg – vial No. 5 and No. 10



**Indications:**

- chronic prostatitis and complications after surgery on the prostate gland

### TRYPsin CRYSTAL

**Generic name:**  
trypsin

**SURGERY**

**COMMERCIAL FORM:**

- lyophilisate for a solution for injection and topical application, 10 mg - vial No. 5 and No. 10



**Indications:**

- bronchiectasis, lung abscesses, exudative pleurisy, postoperative atelectasis, pleural empyema;
- treatment of purulent wounds and burns;
- chronic purulent otitis, purulent sinusitis, maxillary sinusitis;
- acute thrombophlebitis, acute and chronic odontogenic osteomyelitis, inflammatory-dystrophic forms of periodontal disease, acute iridium and iridocyclitis, haemorrhages in the eye chamber and edema of pericardial tissues after injuries and operations, obstruction of tear ducts

### CHYMOTRYPSIN

**Generic name:**  
chymotrypsin

**PULMONOLOGY**

**COMMERCIAL FORM:**

- lyophilisate for a solution for injection, local and topical application, 10 mg – vial No. 5 and No. 10



**Indications:**

- suppurative diseases of the respiratory system (bronchiectasis, pneumonia, lung abscess, atelectasis, exudative pleurisy, empyema, pleura, bronchitis);
- burns, pressure sores, purulent wounds;
- thrombophlebitis, periodontal disease (inflammatory-dystrophic forms);
- fresh extensive central retinal vein thrombosis, acute obstruction of the central retinal artery, vitreous body turbidity of traumatic and inflammatory origin, cataract extraction;
- purulent sinusitis, subacute laryngotracheitis, after tracheostomy to facilitate removal of dense viscous exudate, in acute, subacute, purulent, chronic middle otitis and eustachitis with viscous exudate

### CHYMOPsin

**Generic name:**  
trypsin + chymotrypsin

**PULMONOLOGY / SURGERY**

**COMMERCIAL FORM:**

- lyophilisate for a solution for local and topical application, 50 mg – vial No. 5 and No. 10



**Indications:**

- bronchoectatic disease, lung abscess, atelectasis, exudative pleuritis (for liquefaction of dense viscous sputum and respiratory system remediation);
- purulent sinus, purulent otitis (acute, subacute, chronic), eustachitis with viscous exudate, after tracheostomy to facilitate removal of thick viscous exudate, chronic rhinitis;
- burns, pressure sores, trophic ulcers, purulent wounds (cleaning from purulent-necrotic masses, accelerating healing);
- diseases of the cornea (ulcer, herpetic keratitis); burn of the mucous membrane of the eye, obstruction of the tear ducts, sluggish healing of wounds of the skin of the eyelids

### RIBONUCLEASE

**Active substance:**  
ribonuclease

**INFECTIOUS DISEASES**

**COMMERCIAL FORM:**

- lyophilisate for a solution for injection and topical application, 10 mg - vial No. 10



**Indications:**

- diseases of the respiratory tract with viscous sputum (bronchiectasis, lung abscesses, lung atelectasis, exudative pleurisy);
- periodontal disease, gingivitis, purulent wounds, fistulas, abscesses, trophic ulcers, sinusitis (acute, exacerbation of chronic), otitis media (acute, exacerbation of the chronic, including in the perforated stage), thrombophlebitis;
- tick-borne encephalitis (in severe cases of the disease, in combination with specific gamma globulin)

# PRODUCT LIST

## OTC DRUGS

# OUR PORTFOLIO

## FOOD SUPPLEMENTS



### CANNED MEDICAL BILE

**Active substance:**  
bile of cattle and pigs, canned, frozen

#### ORTHOPEADICS

**COMMERCIAL FORM:**  
• emulsion for external use,  
bottle 100 ml and 250 ml

**Indications:**  
arthralgia, post-traumatic myalgia  
(without violating the integrity of the skin)



### TIMUSOL®

**Ingredients:**  
Echinacea purpurea, dry leaf extract; Schisandra chinensis, dry fruit extract

#### GENERAL THERAPY

**COMMERCIAL FORM:**  
• capsules 300 mg No. 30

**Reinforcement of the immune system.**  
A complex of extracts to maintain the protective function of the body during an increased incidence of SARS and influenza



### LIBEMAKS®

**Ingredients:**  
Sabal palm, dry fruit extract; dioica nettle, dry root extract; antler deer powder; selexen

#### UROLOGY

**COMMERCIAL FORM:**  
• capsules 300 mg No. 45

**Helps maintain prostate health.**  
A complex of extracts and trace elements to eliminate and prevent the development of prostate adenoma, as well as to strengthen men's health

# PRODUCT LIST

## MEDICAL COSMETICS

This line of natural creams is characterized by a combination of the active properties of purified bile with the properties of natural essential oils, chondroprotectors and extracts of medicinal plants

### FORTEVIGAL®

**Ingredients:**  
dry bile (refined), essential oil of fir

#### ORTHOPAEDICS

**COMMERCIAL FORM:**  
• cream, tube 125 ml

**Indications:**

- rheumatism;
- osteochondrosis;
- arthrosis and other diseases



#### BENEFITS

- natural and highly effective components
- balanced composition
- convenient pharmaceutical form and presentation
- convenient application
- pleasant flavour

### FORTEVIGAL®-K

**Ingredients:**  
dry bile (refined), Cosphaderm®VBE, camphor, menthol, eucalyptus essential oil

#### ORTHOPAEDICS

**COMMERCIAL FORM:**  
• cream, tube 125 ml

**Indications:**

- sprains;
- bruises;
- sports injuries



#### BENEFITS

- soft, but strong and prolonged warming effect
- effective elimination of muscle pain
- convenient pharmaceutical form and presentation
- convenient application
- pleasant flavour

### FORTEVIGAL®-GH

**Ingredients:**  
dry bile (refined), glucosamine sulfate, chondroitin sulfate, grapefruit essential oil, orange essential oil

#### ORTHOPAEDICS

**COMMERCIAL FORM:**  
• cream, tube 125 ml

**Indications:**

- joint injuries;
- arthrosis;
- osteochondrosis;
- for restoration of joints



#### BENEFITS

- has a complex effect
- promotes restoration, nutrition and regeneration of joints
- convenient pharmaceutical form and presentation
- convenient application
- pleasant flavour

# PRODUCT LIST

## ACTIVE PHARMACEUTICAL INGREDIENTS

### API SAMPROST®

Prostate extract  
It is used for the preparation of non-sterile dosage forms  
**Commercial form:** substance-powder, double-layer polyethylene package - wrapping paper, 1 kg

### API LYDASE

Hyaluronidase  
Used for the preparation of non-sterile or injectable dosage forms  
**Commercial form:** substance, bottle, 20 g


### API DEOXYRIBONUCLEASE

Deoxyribonuclease  
Used for the preparation of non-sterile or injectable dosage forms  
**Commercial form:** substance, polymer pot, 50 g and 100 g

## OUR GEOGRAPHY

full production cycle: from the synthesis of active pharmaceutical substances to finished dosage forms

pharmaceutical quality management system ISO 9001





# PRODUCTION LAUNCH

ST. PETERSBURG,  
PUSHKIN, PUSHKINSKAYA  
INDUSTRIAL ZONE

land plot area

# 2,74 ha

# Q1 2022

- new production site launch **Q1 2022**
- **411** jobs
- **5 main buildings:**  
finished drugs production building, active pharmaceutical substances production building, office and laboratory building, warehouse building, engineering building
- own steam-gas boiler house operating on natural gas
- API from EERM production capacity (endocrine-enzyme raw materials): 5.000 kg substances (91 kg of lyophilic substances)
- **possibilities of contract bottling and lyophilization: 35 mln vials/year**  
(including the high-tech preparation line, filling and corking of OPTIMA bottles with a capacity of 18 thousand vials/h)
- the main vials format are 2R, 4R (10R, 20R, 50R, 100R vials are optional)
- freeze drying - 25 m<sup>2</sup>
- **100% IPC control**
- compliance with Russian and international standards of pharmaceutical production (GxP standards), incl. environmental standards (closed cycle of turnover of organic solvents, full treatment of industrial effluents)



**We use our unique competencies  
and expertise in the field of biopharmaceutical  
products research and production to improve human  
quality of life and health**

**LLC «Samson-Med»  
Moskovskoe shosse, 13  
Saint Petersburg,  
Russian Federation 196158  
8 800 1000 554  
[www.samsonmed.ru](http://www.samsonmed.ru)**

